0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > EphA2

EphA2

EphA2 Molecule Information

Name:Ephrin type-A receptor 2
Target Synonym:Soluble EPHA2 Variant 1?EC 2.7.10.1?CTRCT6?ARCC2?CTPP1?CTPA?Receptor? EphA2?Ephrin type-A receptor 2?Epithelial cell kinase?EPHA2?EPH Receptor A2?Tyrosine-Protein Kinase Receptor ECK?ECK?EC 2.7.10?EC:2.7.10.1?Epithelial Cell Receptor Protein Tyrosine Kina
Number of Launched Drugs:2
Number of Drugs in Clinical Trials:3
Lastest Research Phase:Approved

EphA2 Protein Product ListCompare or Buy

By Product Status:
By Product Category:
By Species:
By Tag:
By Conjugate:
Cat. No. Species Product Description Structure Purity Feature
EP2-H52H3 Human Human EphA2 Protein, His Tag
EP2-H52H3-structure

EphA2 Molecule Synonym Name

EphA2,ECK

EphA2 Molecule Background

Receptor tyrosine kinase which binds promiscuously membrane-bound ephrin-A family ligands residing on adjacent cells, leading to contact-dependent bidirectional signaling into neighboring cells. The signaling pathway downstream of the receptor is referred to as forward signaling while the signaling pathway downstream of the ephrin ligand is referred to as reverse signaling. Activated by the ligand ephrin-A1/EFNA1 regulates migration, integrin-mediated adhesion, proliferation and differentiation of cells. Regulates cell adhesion and differentiation through DSG1/desmoglein-1 and inhibition of the ERK1/ERK2 (MAPK3/MAPK1, respectively) signaling pathway. Engaged by the ligand ephrin-A5/EFNA5 may regulate lens fiber cells shape and interactions and be important for lens transparency development and maintenance. With ephrin-A2/EFNA2 may play a role in bone remodeling through regulation of osteoclastogenesis and osteoblastogenesis.

EphA2 References

EphA2 Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Regorafenib Monohydrate BAY-73-4506; DAST Approved Bayer Ag Stivarga, Resihance Mainland China Gastrointestinal Stromal Tumors s:15:"Bayer Pharma Ag"; 2012-09-27 Solid tumours; Rectal Neoplasms; Carcinoma, Renal Cell; Colonic Neoplasms; Colorectal Neoplasms; Gastrointestinal Stromal Tumors; Carcinoma, Hepatocellular; Gastrointestinal Neoplasms Details
Dasatinib Hydrate BMS-354825; NSC-732517 Approved Bristol-Myers Squibb Company 施达赛, Spricel, Sprycel, Spraysel Mainland China Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Myelogenous, Chronic, BCR-ABL Positive s:32:"Bristol-Myers Squibb Pharma Eeig"; 2006-06-28 Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia; Leukemia, Myeloid, Accelerated Phase; Leukemia, Myeloid; Leukemia, Lymphoid; Myelodysplastic Syndromes; Scleroderma, Systemic; Blast Crisis; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prostatic Neoplasms; Breast Neoplasms; Leukemia, Myeloid, Chronic-Phase; Leukemia, Myeloid, Acute; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung Details

EphA2 Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
BT-5528 BT5528; BT-5528 Bicycle Therapeutics Details
Dasatinib nanoparticle formulation (Xspray Pharma) Phase 1 Clinical Xspray Pharma Leukemia, Myelogenous, Chronic, BCR-ABL Positive Details
siRNA-EphA2-DOPC Phase 1 Clinical The University Of Texas M.D. Anderson Cancer Center Ovarian Neoplasms; Pancreatic Neoplasms Details

This web search service is supported by Google Inc.

totop